nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclopentolate—BCHE—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.111	0.139	CbGpPWpGaD
Cyclopentolate—Methylphenidate—SLC6A3—Gilles de la Tourette syndrome	0.0578	0.286	CrCbGaD
Cyclopentolate—Dexmethylphenidate—SLC6A3—Gilles de la Tourette syndrome	0.0578	0.286	CrCbGaD
Cyclopentolate—Venlafaxine—SLC6A3—Gilles de la Tourette syndrome	0.0571	0.283	CrCbGaD
Cyclopentolate—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.035	0.0438	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0349	0.0437	CbGpPWpGaD
Cyclopentolate—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0298	0.0374	CbGpPWpGaD
Cyclopentolate—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0297	0.0373	CbGpPWpGaD
Cyclopentolate—Pethidine—SLC6A3—Gilles de la Tourette syndrome	0.0292	0.145	CrCbGaD
Cyclopentolate—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.029	0.0363	CbGpPWpGaD
Cyclopentolate—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0289	0.0362	CbGpPWpGaD
Cyclopentolate—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.027	0.0338	CbGpPWpGaD
Cyclopentolate—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0269	0.0337	CbGpPWpGaD
Cyclopentolate—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0251	0.0314	CbGpPWpGaD
Cyclopentolate—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.025	0.0313	CbGpPWpGaD
Cyclopentolate—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0243	0.0305	CbGpPWpGaD
Cyclopentolate—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0243	0.0304	CbGpPWpGaD
Cyclopentolate—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0227	0.0284	CbGpPWpGaD
Cyclopentolate—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0226	0.0283	CbGpPWpGaD
Cyclopentolate—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0189	0.0237	CbGpPWpGaD
Cyclopentolate—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0188	0.0236	CbGpPWpGaD
Cyclopentolate—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0159	0.0199	CbGpPWpGaD
Cyclopentolate—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0158	0.0198	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.0132	0.0165	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0128	0.0161	CbGpPWpGaD
Cyclopentolate—BCHE—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00842	0.0105	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00837	0.0105	CbGpPWpGaD
Cyclopentolate—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00703	0.00881	CbGpPWpGaD
Cyclopentolate—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00682	0.00855	CbGpPWpGaD
Cyclopentolate—BCHE—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00645	0.00808	CbGpPWpGaD
Cyclopentolate—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00636	0.00796	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00576	0.00721	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00574	0.00719	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00559	0.007	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00557	0.00698	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00521	0.00652	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00519	0.0065	CbGpPWpGaD
Cyclopentolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00493	0.00618	CbGpPWpGaD
Cyclopentolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00492	0.00616	CbGpPWpGaD
Cyclopentolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00479	0.006	CbGpPWpGaD
Cyclopentolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00477	0.00598	CbGpPWpGaD
Cyclopentolate—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00472	0.00591	CbGpPWpGaD
Cyclopentolate—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.0047	0.00589	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—HDC—Gilles de la Tourette syndrome	0.00467	0.00585	CbGpPWpGaD
Cyclopentolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00446	0.00559	CbGpPWpGaD
Cyclopentolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00445	0.00557	CbGpPWpGaD
Cyclopentolate—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00422	0.00529	CbGpPWpGaD
Cyclopentolate—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00421	0.00527	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00376	0.00471	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00374	0.00469	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00365	0.00457	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00365	0.00457	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00363	0.00455	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00363	0.00455	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00359	0.0045	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0034	0.00426	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00339	0.00424	CbGpPWpGaD
Cyclopentolate—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00312	0.00391	CbGpPWpGaD
Cyclopentolate—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00311	0.0039	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00238	0.00298	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00237	0.00297	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00212	0.00266	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00212	0.00265	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00206	0.00258	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00205	0.00257	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00193	0.00241	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00192	0.00241	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00192	0.0024	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00191	0.0024	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00187	0.00234	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00187	0.00234	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00174	0.00218	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00174	0.00218	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00134	0.00168	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00134	0.00168	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00122	0.00153	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00122	0.00152	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00114	0.00143	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00114	0.00142	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00111	0.00138	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.0011	0.00138	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00103	0.00129	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00103	0.00129	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000721	0.000904	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000719	0.000901	CbGpPWpGaD
